Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

July 31, 2007

Study Completion Date

September 30, 2008

Conditions
Multiple Myeloma
Interventions
DRUG

bortezomib

Trial Locations (6)

10021

Memorial Sloan-Kettering Cancer Center, New York

30322

Emory Winship Cancer Institute, Atlanta

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

04263

Roswell Park Cancer Institute, Buffalo

Sponsors
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Roswell Park Cancer Institute

OTHER

collaborator

Emory University

OTHER

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00153920 - Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma | Biotech Hunter | Biotech Hunter